Check out this CNBC article, “Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’ Excerpt:

“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday.

What Richter wrote is both true and shocking. Her analysis lays bare one of the many blatant conflicts of interest in the health care industry.